Towards Personalized Management of Ovarian Cancer

Algethami, Mashael; Kulkarni, Sanat; Sadiq, Maaz T; Tang, Hiu KC; Brownlie, Juliette; Jeyapalan, Jennie N; Mongan, Nigel P; Rakha, Emad A; Madhusudan, Srinivasan

Abstract

Despite advances in surgery and chemotherapy, the overall outcomes for patients with advanced ovarian cancer remain poor. Although initial response rates to platinum-based chemotherapy is about 60–80%, most patients will have recurrence and succumb to the disease. However, a DNA repair–directed precision medicine strategy has recently generated real hope in improving survival. The clinical development of PARP inhibitors has transformed lives for many patients with BRCA germline-deficient and/or platinum-sensitive epithelial ovarian cancers. Antiangiogenic agents and intraperitoneal chemotherapy approaches may also improve outcomes in patients. Moreover, evolving immunotherapeutic opportunities could also positively impact patient outcomes. Here we review the current clinical state of PARP inhibitors and other clinically viable targeted approaches in ovarian cancer.

Citation

Algethami, M., Kulkarni, S., Sadiq, M. T., Tang, H. K., Brownlie, J., Jeyapalan, J. N., …Madhusudan, S. (2022). Towards Personalized Management of Ovarian Cancer. Cancer Management and Research, 14, 3469-3483. https://doi.org/10.2147/CMAR.S366681

• Journal Article Type: Review
• Acceptance Date: Dec 10, 2022
• Online Publication Date: Dec 15, 2022
• Publication Date: 2022
• Deposit Date: Apr 9, 2023
• Publicly Available Date: Apr 18, 2023
• Journal: Cancer Management and Research
• Print ISSN: 1179-1322
• Publisher: Dove Press
• Peer Reviewed: Peer Reviewed
• Volume: 14
• Pages: 3469-3483
• DOI: https://doi.org/10.2147/CMAR.S366681
• Keywords: Oncology
• Public URL: https://nottingham-repository.worktribe.com/output/14895158
• Publisher URL: https://www.dovepress.com/towards-personalized-management-of-ovarian-cancer-peer-reviewed-fulltext-article-CMAR